Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Incyte (INCY) PT Lowered to $72 at RBC Capital
August 1, 2018 8:50 AM EDTRBC Capital lowered its price target on Incyte (NASDAQ: INCY) to $72.00 (from $74.00) while maintaining a Sector Perform rating.
... MoreIncyte (INCY) Q2 Revenue Tops Views
July 31, 2018 7:13 AM EDTIncyte (NASDAQ: INCY) reported Q2 EPS of $0.26, $0.09 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $521.52 million versus the consensus estimate of $473.78 million.
2018 Financial... More
